Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

por Wharton, Sean, Yin, Peter, Burrows, Melonie, Gould, Errol, Blavignac, Jessica, Christensen, Rebecca A. G., Kamran, Elham, Camacho, Fernando, Barakat, Maxime
Publicado 2021

The i-ACT™ in Obesity educational intervention: a pilot study on improving Canadian family physician care in obesity medicine

por Wharton, Sean, Macklin, David, Morin, Marie-Philippe, Blavignac, Jessica, Menzies, Stuart, Garofalo, Laura, Francisco, Michelle A., Thomas, Carol, Barakat, Maxime
Publicado 2022